SPOTLIGHT

STAY CONNECTED

LinkedIn  

STARTUP NEWS

WUXI NEWS

WuXi NextCODE AI Points to New Therapeutic Approaches to Cardiovascular Disease and Cancer in...

We are thrilled about WuXi NextCODE's contribution of its artificial intelligence (AI) and sequencing teams to the discovery of a novel mechanism regulating how blood vessels grow. The study, 'FGF-dependent metabolic control...

WuXi AppTec Completes Acquisition of HD Biosciences

We are pleased to announce WuXi has completed the acquisition of HD Biosciences (HDB), a leading biology focused preclinical drug discovery contract research organization (CRO). Shanghai-based HD Biosciences' plate-based pharmacology and screening capability...

WuXi NextCODE Raises $75 Million in Series B Financing to Accelerate Growth of Global...

WuXi would like to congratulate WuXi NextCODE for raising $75 million in Series B financing, led by the company's current investors Temasek and Yunfeng Capital. WuXi NextCODE will focus the use of proceeds...

LabNetwork Integrates with Reaxys to Offer Seamless Experience from Chemistry Research to Purchase

We look forward to the new collaboration between LabNetwork, WuXi AppTec’s global chemistry ecommerce platform company, and Elsevier, a world-leading provider of scientific, technical and medical information products and services. Under the...

WuXi Biologics Receives Asia-Pacific Best Bioprocessing Excellence Award from IMAPAC

We are pleased to announce that WuXi Biologics  has received the 2017 Asia-Pacific Best Bioprocessing Excellence Award from IMAPAC, a leading consulting firm. WuXi Biologics has been recognized for its outstanding performance for...

FDA UPDATES